A clinical trial of NOX-A12 in patients with mutiple myeloma who have previously been treated and who will be receiving bortezomib and dexamethasone treatment.

Registry ID
EUCTR2011-004651-40
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
NOXXON Pharma AG
Start date
2012-03-05
Completion date
2015-09-30
Last update
2026-08-16

Conditions

Summary

To assess the safety and tolerability of NOX-A12 alone (pilot group only) and in combination with VD To determine the overall response rate according to IMWG uniform response criteria (ORR = best response at least partial response(PR))

Locations

View on source registry